Quince Therapeutics reports biotechnology, clinical-development and corporate restructuring updates tied to its rare-disease focus. The company’s AIDE technology is a drug/device platform designed to encapsulate drugs in a patient’s own red blood cells, and its lead asset eDSP has been studied in Ataxia-Telangiectasia, a rare pediatric neurodegenerative disease.
Recurring news includes eDSP clinical data, scientific presentations and publications, business updates, financial results, debt-settlement activity and the company’s evaluation of strategic alternatives. Recent company communications also reflect the decision to cease clinical development of eDSP following Phase 3 NEAT trial results and to preserve cash while reviewing available corporate options.
Quince Therapeutics (QNCX) has relaunched as IRulya Therapeutics, focusing on clinical development of inhaled rapamycin candidate LAM-001 for pulmonary diseases. Shares will trade as IRLA on the Nasdaq Capital Market from October 12, 2026. The change follows the completed Orphai merger and a May private placement with approximately $115 million in upfront gross proceeds.
Cash was $116 million at June 30, 2026; the company expects funding through end-2028. It anticipates Phase 2 data for post-transplant bronchiolitis obliterans syndrome in Q1 2027 and pulmonary hypertension associated with interstitial lung disease in Q1 2028, and plans a sarcoidosis-associated pulmonary hypertension study starting in Q4 2026. Brigette Roberts becomes CEO, John Militello CFO and Keith Fandrick COO. Preferred shares will convert October 9, subject to holder ownership limits; approximately 10,841,470 common shares are expected afterward.
Quince Therapeutics (QNCX) will host a virtual key opinion leader event on September 28, 2026, from 12:30–2:00 PM ET to discuss PH-ILD, BOS, and its investigational therapy LAM-001.
The session will feature clinical experts reviewing current and emerging treatment landscapes, mTOR inhibition as a potential disease-modifying approach, and the inhaled once-daily DPI formulation LAM-001, which is in Phase 2 trials for PH-ILD and BOS. Data from a Phase 2a pulmonary hypertension study and designs of ongoing Phase 2 BOS and Phase 2b PH-ILD studies will be presented, followed by a live Q&A.
Quince Therapeutics (QNCX) will participate in two investor conferences in September 2026. The company’s senior management will join a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026 at 2:45 p.m. ET, and will provide a company presentation at the H.C. Wainwright 28th Annual Global Investment Conference starting September 14, 2026. Webcasts and replays of both events will be available through the Investors section of Quince’s website.
Quince Therapeutics (Nasdaq: QNCX) reported second quarter 2026 results highlighting the completed stock‑for‑stock acquisition of Orphai Therapeutics, adding lead asset LAM‑001, an inhaled rapamycin for multiple serious pulmonary diseases. Concurrently, the company closed a private placement with $115 million in gross upfront proceeds and potential for up to an additional $83 million upon warrant exercise.
Cash and cash equivalents were $116 million as of June 30, 2026, which Quince expects will fund operations through year‑end 2028. R&D expense was $5.5 million versus $6.6 million a year earlier, while G&A rose to $16.6 million, driven by non‑cash stock‑based compensation and higher professional fees. Net loss was $75.5 million, or $12.31 per share, compared with a $16.0 million loss in the prior‑year quarter. Quince advanced LAM‑001 into Phase 2b PH‑ILD and continued a Phase 2 BOS trial, supported by Phase 2a data showing clinically meaningful improvements in six‑minute walk distance and pulmonary vascular resistance.
Quince Therapeutics (Nasdaq: QNCX) formed a Scientific Advisory Board to guide development of LAM-001, an inhaled rapamycin (mTOR inhibitor) targeting multiple serious pulmonary indications, including PH-ILD, BOS, and SAPH.
The SAB includes internationally recognized leaders in pulmonary vascular disease, advanced lung disease, lung transplantation, and sarcoidosis, who have led pivotal clinical trials and major research programs in these areas.
Quince Therapeutics (Nasdaq: QNCX) announced settlement of its European Investment Bank loan obligations effective March 27, 2026. The company paid $5.5 million to fully satisfy approximately $16.4 million of outstanding EIB debt, enabling restructuring and evaluation of strategic alternatives.
Management says the settlement removes a substantial overhang that constrained flexibility and supports pursuit of merger, reverse merger, asset sale, or other strategic transactions aimed at maximizing shareholder value.
Quince Therapeutics (Nasdaq: QNCX) engaged LifeSci Capital as its exclusive financial advisor on February 9, 2026 to evaluate strategic alternatives and assist with restructuring of the company’s liabilities.
Options under review may include partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions; the company will not comment further until the Board approves any specific action.
Quince Therapeutics (Nasdaq: QNCX) reported topline results from the pivotal Phase 3 NEAT trial of eDSP in Ataxia-Telangiectasia. The trial (n=105) failed to meet the primary RmICARS endpoint (difference -1.30; p=0.0851) and a key secondary CGI-S endpoint (p=0.522).
eDSP was generally well tolerated with no clinically meaningful safety concerns. The company will cease clinical development of eDSP and intends to preserve cash while exploring available options.
Quince Therapeutics (NASDAQ: QNCX) presented previously published safety data on long-term eDSP in children with Ataxia-Telangiectasia at the British Paediatric Neurology Association Annual Meeting, Glasgow, January 28-30, 2026.
Key highlights: stable height and weight z-scores, no corticosteroid-related growth suppression or weight gain, no adrenal insufficiency confirmed, and no glucose homeostasis concerns; routine monitoring recommended.
Quince Therapeutics (Nasdaq: QNCX) announced the last patient last visit in its pivotal Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP) for Ataxia-Telangiectasia (A-T).
The company enrolled 105 participants (83 in the 6–9 year primary cohort; 22 aged ≥10), executed the study under a Special Protocol Assessment, and reports low discontinuation rates and an independent data safety monitoring board that met three times with no safety concerns. Quince expects to report topline results in the middle of Q1 2026. Most participants (all but one) transitioned to an open-label extension.